Search

Your search keyword '"Karen Thudium Mueller"' showing total 29 results

Search Constraints

Start Over You searched for: Author "Karen Thudium Mueller" Remove constraint Author: "Karen Thudium Mueller"
29 results on '"Karen Thudium Mueller"'

Search Results

1. Monitoring of tisagenlecleucel transgene DNA using a quantitative polymerase chain reaction assay

2. Tisagenlecleucel Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor–T Cells

3. Supplementary Data from Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia

4. Data from Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia

5. Table S1 from Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction

6. Figure S2 from Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction

7. Data from Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction

8. Supplementary Data from Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia

9. Data from Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia

10. Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma

11. Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia

12. Current and Next Steps Toward Prediction of Human Dose for Gene Therapy Using Translational Dose‐Response Studies

13. Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction

14. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL

15. Tisagenlecleucel Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor–T Cells

16. Monitoring of tisagenlecleucel transgene DNA using a quantitative polymerase chain reaction assay

17. Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia

18. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

19. The role of clinical pharmacology across novel treatment modalities

20. Impaired tumor death receptor signaling drives resistance to CAR T cell therapy

21. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia

22. Abstract CT237: Evaluation of in vivo chimeric antigen receptor (CAR) transgene levels in patients (pts) treated with tisagenlecleucel

23. Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis

24. CTL019 Clinical Pharmacology and Biopharmaceutics in Pediatric Patients with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

25. Evaluation of In Vivo CAR Transgene Levels in Relapsed/Refractory Pediatric and Young Adult ALL and Adult DLBCL Tisagenlecleucel-Treated Patients

26. Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia

27. Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients

28. Considerations for tisagenlecleucel dosing rationale

29. Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+ Leukemia

Catalog

Books, media, physical & digital resources